Patients with womb cancer are not being tested for a genetic condition that increases their chance of developing further cancers, a study has found.

As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a new study sheds light on whether patients are opting for it. In a study of 591 women with early stage breast cancer who completed five years of endocrine therapy, 47% decided to continue the treatment.

The research focuses on the deadliest variant of prostate cancer and lays the foundation for its molecular cataloguing.

The publication is the result of a nationwide collaborative effort among multiple research groups, coordinated by the team led by Arkaitz Carracedo.

Published in the prestigious journal Genome Biology, the study suggests that the ability of tumor cells to modify the behavior of normal cells to their advantage is a key factor in the progression of the disease.

The joint research laboratory established between CIC bioGUNE and the Basurto University Hospital has enabled the generation of a highly valuable collection of samples and molecular data for future investigations.